Vaxcyte, Inc.
PCVX
Peringkat dalam Saham
#2081
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage,... Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Harga Saham
$64.29
Kapitalisasi Pasar
$9.86B
Perubahan (1 hari)
1.05%
Perubahan (1 tahun)
51.66%
Negara
US
Perdagangan Vaxcyte, Inc. (PCVX)
Kategori
Healthcare
Laba untuk Vaxcyte, Inc. (PCVX)
Laba pada Jun 2026 TTM: $-1.06B
Menurut laporan keuangan terbaru dari Vaxcyte, Inc., laba saat ini perusahaan adalah $-1.06B. Pada tahun 2023, perusahaan memperoleh laba sebesar $-402.27M, penurunan dibandingkan dengan laba tahun 2022 sebesar $-223.49M. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Vaxcyte, Inc. dari 2017 hingga 2026
Laba pada akhir setiap tahun
| Tahun | Laba | Mengubah |
|---|---|---|
| 2026 (TTM) | $-1.06B | 129.40% |
| 2024 | $-463.93M | 15.33% |
| 2023 | $-402.27M | 80.00% |
| 2022 | $-223.49M | 123.31% |
| 2021 | $-100.08M | 12.17% |
| 2020 | $-89.22M | 77.46% |
| 2019 | $-50.27M | 70.51% |
| 2018 | $-29.49M | 71.05% |
| 2017 | $-17.24M | 0.00% |
Laba untuk perusahaan serupa atau pesaing
| Perusahaan | Laba | Perbedaan Laba | Negara |
|---|---|---|---|
| $5.27B | -595.64% |
US
|
|
| $-3.09B | 190.06% |
US
|
|
| $-4.02B | 277.37% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -283.29% |
NL
|
